The sales are small relative to company size and may be routine portfolio management; no immediate concern, but monitor for increased selling in next quarter.
ALKS drugs
ALKS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $30.24entry
- T+1 · 9mo ago −3.47%α −2.56% · $29.19
- T+5 · 8mo ago −5.92%α −4.71% · $28.45
- T+20 · 8mo ago −0.63%α +7.31% · $30.05
- T+60 · 6mo ago +23.52%α +14.20% · $37.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three executives at Alkermes sold shares in the past week, including two open-market sales by EVPs Gaffin and Parisi totaling over $320K in proceeds. A portion of the activity involves derivative exercises with no cash impact.
Key Financial Metrics
Key Facts
- EVP David Gaffin sold 4,068 shares in two transactions for $120,108 total proceeds.
- Interim VP Finance Samuel Parisi sold 6,890 shares for $201,808.
- EVP Craig Hopkinson exercised 5,000 derivative securities worth $96,700 but did not sell in the open market.
- Total open-market sales amount to $321,916, representing less than 0.01% of Alkermes' $4.9B market cap.
- All transactions occurred at market prices between $29.29 and $29.76.
Financial Impact
$321,916 in open-market sales by insiders
Risk Factors
- Perception of insider pessimism if selling continues ahead of earnings or clinical data readouts.
- Concentration of sales among senior executives could raise questions if trend persists.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (4 trades, 7d window) | cluster-ALKS-1772673936036 |
Track record
23 reports on ALKS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.88% at T+60 after the May 12, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $46.98 Now $46.53 −0.96% settles Feb 10
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
- Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
- Sep 16, 20268w ago 8-K Neutral 2/10 Entry $46.07 Now $46.53 +1.00% settles Dec 10
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
- Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers